Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines

Ssemaganda, Aloysious; Giddam, Ashwini Kumar; Zaman, Mehfuz; Skwarczynski, Mariusz; Tóth, István; Stanisic, Danielle I.; Good, Michael F.

doi:10.3389/fimmu.2019.00135

Cited by 19 publications

(20 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, research and development of malaria vaccines for liver and blood stages of the parasites face enormous challenges, as many vaccine candidates are poorly immunogenic and have shown toxicity in mice. Plasmodium can evade immune responses via a few reported mechanisms [110], therefore, non-natural (absent in infected individuals) immune responses stimulated by vaccine could overwhelm Plasmodium defense systems [111,112].…”

Section: Challenges and Prospectsmentioning

confidence: 99%

“…For future efforts, many of the major problems in vaccine development can be minimized through the following: (a) using new adjuvants to improve immunogenicity; (b) discovery of new potent classical and cryptic epitopes [115] from a variety of P. falciparum proteins [116][117][118][119]; (c) modification to, and development of new, vaccine delivery systems, for example, nanoparticulate liposomal forms [112]; and (d) the use of multi-antigenic vaccines, including multiple epitopes from both blood and liver stages of malaria [57,119].…”

Section: Challenges and Prospectsmentioning

confidence: 99%

See 1 more Smart Citation

Progress in the Development of Subunit Vaccines against Malaria

et al. 2020

Self Cite

View full text Add to dashboard Cite

Malaria is a life-threatening disease and one of the main causes of morbidity and mortality in the human population. The disease also results in a major socio-economic burden. The rapid spread of malaria epidemics in developing countries is exacerbated by the rise in drug-resistant parasites and insecticide-resistant mosquitoes. At present, malaria research is focused mainly on the development of drugs with increased therapeutic effects against Plasmodium parasites. However, a vaccine against the disease is preferable over treatment to achieve long-term control. Trials to develop a safe and effective immunization protocol for the control of malaria have been occurring for decades, and continue on today; still, no effective vaccines are available on the market. Recently, peptide-based vaccines have become an attractive alternative approach. These vaccines utilize short protein fragments to induce immune responses against malaria parasites. Peptide-based vaccines are safer than traditional vaccines, relatively inexpensive to produce, and can be composed of multiple T- and B-cell epitopes integrated into one antigenic formulation. Various combinations, based on antigen choice, peptide epitope modification and delivery mechanism, have resulted in numerous potential malaria vaccines candidates; these are presently being studied in both preclinical and clinical trials. This review describes the current landscape of peptide-based vaccines, and addresses obstacles and opportunities in the production of malaria vaccines.

show abstract

Section: Challenges and Prospectsmentioning

confidence: 99%

Section: Challenges and Prospectsmentioning

confidence: 99%

Progress in the Development of Subunit Vaccines against Malaria

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the CSP part of RTS, S is an antigenic polymorphism, and T cell epitopes present on the CS protein that are incorporated into the vaccine are also polymorphic. To address this problem, the newest generation of this vaccine is coformulated with Matrix-M, a saponin-based liposomal adjuvant [32]. However, the vaccine protection against P. falciparum has not been achieved due to the short-lived memory cells and the evasion mechanisms of the parasite [33].…”

Section: Liposomesmentioning

confidence: 99%

“…Although the vaccine did not show sterile protection, it induced responses on blood stage parasites and lower rates of parasite growth in human volunteers vaccinated with PEV3A, compared to unvaccinated controls [43]. GlaxoS-mithKline plc is working to improve the coformulated RTS, S vaccine using Matrix-M, a saponin-based liposomal adjuvant [32].…”

Section: Np-investing Companies and Clinical Trialsmentioning

confidence: 99%

Nanoparticle-based vaccines

Díaz-Arévalo

Zeng

2020

Nanopharmaceuticals

View full text Add to dashboard Cite

“…26 The major challenges to the development of vaccines against malaria include a failure to induce strong innate immune responses and a lack of potentiation and maintenance of adaptive immune responses. 27 There have been efforts to develop malaria vaccines since the 1940s. 28 Despite several promising candidates, an effective vaccine that provides long-lived protection against malaria has not been developed.…”

Section: Introductionmentioning

confidence: 99%

Variations in killer-cell immunoglobulin-like receptor and human leukocyte antigen genes and immunity to malaria

et al. 2020

View full text Add to dashboard Cite

Malaria is one of the deadliest infectious diseases in the world. Immune responses to Plasmodium falciparum malaria vary among individuals and between populations. Human genetic variation in immune system genes is likely to play a role in this heterogeneity. Natural killer (NK) cells produce inflammatory cytokines in response to malaria infection, kill intraerythrocytic Plasmodium falciparum parasites by cytolysis, and participate in the initiation and development of adaptive immune responses to plasmodial infection. These functions are modulated by interactions between killer-cell immunoglobulin-like receptors (KIRs) and human leukocyte antigens (HLAs). Therefore, variations in KIR and HLA genes can have a direct impact on NK cell functions. Understanding the role of KIRs and HLAs in immunity to malaria can help to better characterize antimalarial immune responses. In this review, we summarize the different KIRs and HLAs associated with immunity to malaria thus far.

show abstract

Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines

Cited by 19 publications

References 187 publications

Progress in the Development of Subunit Vaccines against Malaria

Progress in the Development of Subunit Vaccines against Malaria

Nanoparticle-based vaccines

Variations in killer-cell immunoglobulin-like receptor and human leukocyte antigen genes and immunity to malaria

Contact Info

Product

Resources

About